Advertisement

Abiraterone Acetate/Prednisone Combination Delays Decline in Quality of Life in Men With Metastatic Prostate Cancer

Advertisement

Key Points

  • Abiraterone acetate and prednisone significantly prolonged the time until clinically meaningful worsening of pain intensity as well as deterioration in quality of life compared to patients receiving placebo and prednisone.
  • Patients reported a more than 8-month delay in progression of pain, and a more than 4-month delay in quality of life deterioration.
  • Significant improvements were seen in how pain interferes with daily activities, and time until opiate use.

According to a study published in The Lancet Oncology, abiraterone acetate (Zytiga) taken in conjunction with prednisone significantly delays progression of pain and quality of life deterioration in men with metastatic castration-resistant prostate cancer. The study was led by Ethan Basch, MD, Director of the Cancer Outcomes Research Program at the University of North Carolina Lineberger Comprehensive Cancer Center.

“The majority of men with metastatic prostate cancer experience pain that is often debilitating and can have a profound impact on their ability to function, sleep, and work, and their enjoyment of life. Pain is a central problem in prostate cancer and managing pain remains a major challenge,” said Dr. Basch.

“Patients with cancer experience many symptoms related to their disease and to drug side effects, but this information is generally neither measured rigorously in clinical trials nor included in U.S. drug labels.  As a result, patients often have incomplete information about how they may expect to feel with a new therapy. This study addresses this information gap towards better-informed decisions,” he said.

Study Details

In the study, researchers measured the pain and quality of life impact of abiraterone acetate when added to prednisone and administered to 1,088 patients with metastatic castration-resistant prostate cancer at 151 sites in the United States, Europe, Canada and Australia. The randomized trial enrolled patients who had experienced little or no pain at the outset, prescribing abiraterone acetate and prednisone to 546 of the enrollees and placebo plus prednisone to the remainder.

The design of the study emphasized the importance of patient reported-outcomes in evaluating new treatments. In previous publications, Dr. Basch has shown the importance of evaluating how treatments impact how people feel and function during drug development.

The study tracked the progression of pain intensity, the time until patients needed opiates to control pain, and patients’ quality of life using validated questionnaires. Patients reported their pain intensity on a scale of 1 to 10 as well as the amount that pain interfered with their sleep, mood, and ability to conduct daily activities via the Brief Pain Inventory.

Significant Delay in Progression of Pain

The combination of abiraterone acetate and prednisone significantly prolonged the time until clinically meaningful worsening of pain intensity as well as quality of life deterioration compared to patients receiving the placebo and prednisone. Patients reported a more than 8-month delay in progression of pain, and a more than 4-month delay in quality of life deterioration.  Significant improvements were also seen in how pain interferes with daily activities, and time until opiate use.

Pain is a significant predictor of overall survival, and the ability to delay suffering represents a meaningful clinical benefit to patients, according to Dr. Basch.  The delay of pain also allows patients to forgo the use of opiates and other pain medications for longer periods, a benefit since those medications also cause negative side effects that deteriorate quality of life.

“The design of this study provides a path forward for future research to utilize patient-centered endpoints,” said Dr. Basch.  “Not only does it provide essential information about the properties of abiraterone acetate, but it demonstrates the feasibility of rigorously measuring symptoms in a large multi-national study.  It also helps identify areas of needed future methodological research.”

The study was sponsored by Janssen Research & Development. For full author disclosures, visit www.thelancet.com.

The content in this post has not been reviewed by the American Society of Clinical Oncology, Inc. (ASCO®) and does not necessarily reflect the ideas and opinions of ASCO®.


Advertisement

Advertisement



Advertisement